Kiniksa Pharmaceuticals, Ltd. announces that the company and its President and Chief Operating Officer, Stephen Mahoney, have mutually agreed that Mr. Mahoney will transition to an advisory role on November 15, 2019 through the end of the calendar year before leaving the company to pursue new opportunities. Mr. Mahoney has played an important role in helping to build the company’s experienced team that is strongly positioned to further advance the company’s clinical-stage pipeline. The company does not have any current plans to appoint a new President and Chief Operating Officer. Thomas Beetham, EVP, Corporate Development & Operations, Chief Legal Officer of the company, and Qasim Rizvi, SVP, Operations and Chief Commercial Officer of the company, will assume additional responsibilities and continue to report directly to Sanj K. Patel, Chief Executive Officer and Chairman of the Board of the company.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
KINIKSA PHARMACEUTICALS, LTD. 
